Our study demonstrates that combined treatment with two inhibitors counteracting the activity of two different signaling pathways involved in neoplastic transformation and progression, such as those activated by ErbB and Hh, is more effective than the single treatments in reducing MM growth in vitro and in vivo. The gene discussed is EGFR; the disease is Miyoshi myopathy.